MC2 Therapeutics - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsMC2 Therapeutics

MC2 Therapeutics

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

No data

Company Revenue

No data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Wynzora	Betamethasone, Calcipotriene	2020-07-20	2027-2039	Psoriasis , Atopic dermatitis , Pruritus ani , Inflammation , Facial dermatoses , Seborrheic dermatitis , Foot dermatoses , Hand dermatoses , Scalp dermatoses , Leg dermatoses , Mycoses , Oral candidiasis , Vulvovaginal candidiasis , Tinea pedis , Cutaneous candidiasis

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

vasoconstriction

,

photoallergic dermatitis

,

phototoxic dermatitis

,

therapeutic equivalency

,

,

,

biological availability

,

,

,

non-hodgkin lymphoma

,

,

precursor cell lymphoblastic leukemia-lymphoma

,

lymphoid leukemia

,

retinal detachment

,

vascular diseases

,

macular degeneration

,

wet macular degeneration

,

polypoidal choroidal vasculopathy

,

alzheimer disease

,

,

borrelia infections

,

rheumatoid arthritis

,

,

,

,

small cell lung carcinoma

,

streptococcal infections

,

prostatic neoplasms

,

type 2 diabetes mellitus

,

diabetes mellitus

,

,

renal cell carcinoma

,

,

hepatocellular carcinoma

,

,

liver neoplasms

,

gastrointestinal stromal tumors

,

,

multiple sclerosis

,

,

,

multiple organ failure

,

,

facial paralysis

,

,

premature birth

,

bacterial vaginosis

,

vaginal diseases

,

,

venous thromboembolism

,

,

venous thrombosis

,

pulmonary embolism

,

,

intracranial thrombosis

,

thromboembolism

,

intracranial sinus thrombosis

,

,

,

contact dermatitis

,

bacterial skin diseases

,

,

,

asymptomatic infections

Microcrystalline cellulose

,

therapeutic equivalency

,

,

,

,

hematologic neoplasms

,

non-hodgkin lymphoma

,

,

hodgkin disease

,

,

lupus nephritis

,

systemic lupus erythematosus

,

,

multiple sclerosis

,

healthy volunteers/patients

,

,

,

atrophic vaginitis

alopecia areata

,

localized scleroderma

,

,

vasoconstriction

,

photoallergic dermatitis

,

phototoxic dermatitis

,

healthy volunteers/patients

,

squamous cell neoplasms

,

systemic scleroderma

,

,

breast neoplasms

,

,

,

organ transplantation

,

drug-related side effects and adverse reactions

,

mesenchymal stem cell transplantation

,

,

,

,

,

radiodermatitis

,

atopic dermatitis

,

squamous cell carcinoma

,

,

basal cell carcinoma

,

carcinoma in situ

,

,

actinic keratosis

,

,

connective tissue diseases

,

skin and connective tissue diseases

,

,

,

,

coronary artery disease

,

myocardial ischemia

,

atherosclerosis

,

erythema multiforme

,

papulosquamous skin diseases

,

contact dermatitis

,

graft vs host disease

,

,

topical administration

,

allergic contact dermatitis

,

insulin resistance

,

blood coagulation disorders

,

blood platelet disorders

,

hemostatic disorders

,

coagulation protein disorders

,

oral lichen planus

,

,

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use